As the former Statistical Director of the University of Maryland Cancer Center, Dr. Thompson has been involved in numerous Phase I studies associated with establishing the maximum tolerated dose in the human setting. He is experienced in using modified Fibonacci searches and the 3+3 design to determine the final dose for your treatment. With the use of StudyCTMS, C-TASC staff are able to conduct multi-center Phase I studies to complete this phase more rapidly.